These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 6337292)

  • 41. Adoptive transfer of resistance to murine retrovirus-induced immune suppression.
    Gilmore GL
    Cell Immunol; 1996 Apr; 169(1):24-9. PubMed ID: 8612290
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Suppression of Friend leukemia cell-induced tumours by cellular preparations of Candida albicans.
    Cassone A; Scaringi L; Pesce CD; Titti F; Bistoni F; Marconi P; Rossi GB
    Microbiologica; 1983 Jul; 6(3):207-20. PubMed ID: 6355774
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of whole-body hyperthermia and cyclophosphamide on natural killer cell activity in murine erythroleukemia.
    Shen RN; Hornback NB; Shidnia H; Lu L; Broxmeyer HE; Brahmi Z
    Cancer Res; 1988 Aug; 48(16):4561-3. PubMed ID: 3165052
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A radiosensitive T-lymphocyte associated with resistance of DBA/2 mice harboring Friend leukemia virus-dormant infections to transplantable Friend leukemia virus-erythroleukemia cells.
    DiCicco LM; Truitt GA; Wheelock EF
    Cancer Res; 1986 Jan; 46(1):127-32. PubMed ID: 3509990
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunoprotective determinants in friend murine leukemia virus envelope protein.
    Hasenkrug KJ; Brooks DM; Robertson MN; Srinivas RV; Chesebro B
    Virology; 1998 Aug; 248(1):66-73. PubMed ID: 9705256
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy.
    Giampietri A; Bonmassar A; Puccetti P; Circolo A; Goldin A; Bonmassar E
    Cancer Res; 1981 Feb; 41(2):681-7. PubMed ID: 7448813
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of adoptive immune transfers on murine leukemia virus-infection of rats.
    Hein A; Czub S; Xiao LX; Schwender S; Dörries R; Czub M
    Virology; 1995 Aug; 211(2):408-17. PubMed ID: 7645245
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Experimental Escherichia coli 06 infection in mice. II. Protective factors of immunity after immunosuppression.
    Ahlstedt S
    Scand J Infect Dis Suppl; 1980; Suppl 24():216-9. PubMed ID: 7010558
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of in vivo Friend leukemia virus infection on levels of serum thymic factors and on selected T-cell functions in mice.
    Tonietti G; Rossi GB; Del Gobbo V; Accinni L; Ranucci A; Titti F; Premrov MG; Garaci E
    Cancer Res; 1983 Sep; 43(9):4355-63. PubMed ID: 6347370
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pathogenesis of age dependent paralysis by a temperature sensitive mutant (tsl) of Moloney murine leukemia virus-TB.
    Prasad G; Wong PK
    Indian J Exp Biol; 1992 Sep; 30(9):814-8. PubMed ID: 1478716
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells.
    Hinkula J; Walther-Jallow L; Laurén A; Mäkitalo B; Oberg M; Wahren B; Fenyö EM; Spetz AL
    Vaccine; 2009 Oct; 27(46):6424-31. PubMed ID: 19549607
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetic control of in vitro NK-activity and in vivo resistance to tumors.
    Kärre K; Klein GO; Kiessling R; Klein G
    Tokai J Exp Clin Med; 1983 Dec; 8(5-6):429-48. PubMed ID: 6681339
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Distribution of Fv-4 resistant gene product in Friend leukemia virus-resistant Fv-4r mouse strain.
    Kitagawa M; Aizawa S; Kamisaku H; Sado T; Ikeda H; Hirokawa K
    Exp Hematol; 1996 Oct; 24(12):1423-31. PubMed ID: 8913289
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Correlation of suppressed natural killer cell activity with altered host resistance models in B6C3F1 mice.
    Wilson SD; McCay JA; Butterworth LF; Munson AE; White KL
    Toxicol Appl Pharmacol; 2001 Dec; 177(3):208-18. PubMed ID: 11749120
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
    Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
    Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations.
    Evans R; Fuller JA; Christianson G; Krupke DM; Troutt AB
    Cell Immunol; 1997 Jul; 179(1):66-73. PubMed ID: 9259773
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Inhibition of the effect of immunocytotherapy in leukemia in mice under stress and the possibilities of its withdrawal].
    Sukhikh GT
    Biull Eksp Biol Med; 1984 Dec; 98(12):694-6. PubMed ID: 6542442
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors.
    Cheever MA; Greenberg PD; Fefer A
    J Immunol; 1980 Aug; 125(2):711-4. PubMed ID: 6156213
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lack of correlation between natural killer activity and tumor growth control in nude mice with different immune defects.
    Fodstad O; Hansen CT; Cannon GB; Statham CN; Lichtenstein GR; Boyd MR
    Cancer Res; 1984 Oct; 44(10):4403-8. PubMed ID: 6467201
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hematopoietic stem cells in Friend murine leukemia virus-infected mice undergoing chemotherapy: effects of 5-FU.
    Seidel HJ; Kreja L
    Cancer Treat Rep; 1982 Nov; 66(11):1949-56. PubMed ID: 7139639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.